Answers are grounded in this paper and cite their sources.
For accurate activity measurements and to comply with EU regulations traceability is required. For alpha emitters of interest for emerging targeted alpha therapies (TAT), like 211 At, standardised samples are not readily available. The use of gamma spectrometry can come with high uncertainties due to its reliance on decay data for gamma emissions. A new method for determining the activity of 211 At in a clinical setting is proposed, i.e. on-site measurement, using absolute 4pi-alpha liquid scintillation counting (LSC) with thresholding on a portable TDCR counter. The method focuses on measuring only the alpha particles and not the electrons, which emission intensities come with a higher uncertainty. Using the absolute LSC method the relative expanded measurement uncertainty was 2.2 % ( k = 2). A comparison using gamma spectrometry and the more readily available high purity germanium (HPGe) detector, the relative expanded uncertainty was 12 % ( k = 2). The largest contribution to the much higher uncertainty of the gamma spectrometry comes from the uncertainties in the decay data. Using a portable TDCR-detector is a viable approach to establishing traceability for 211 At, where transportation to a national metrology lab is not feasible. With better decay data the uncertainty of the gamma spectrometry can be reduced by at least one third, which would make it a better alternative when absolute measurements are not available. • Accurate activity measurements and optimised treatments necessitates traceability. • Standardised samples for many targeted alpha therapy nuclides are not available. • A portable TDCR is an option to fill this gap for At-211 by on-site measurements.
No takes yet. Share an insight, caveat, or question.
Leidermark et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: